Kufor–Rakeb syndrome

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Kufor–Rakeb syndrome
Synonyms	Parkinsonism with spasticity, Parkinsonism-spasticity syndrome
Pronounce	N/A
Specialty	Neurology, Genetics
Symptoms	Parkinsonism, spasticity, dystonia, cognitive impairment
Complications	N/A
Onset	Childhood to early adulthood
Duration	Progressive
Types	N/A
Causes	Mutations in the ATP13A2 gene
Risks	Family history of the condition
Diagnosis	Genetic testing, clinical evaluation
Differential diagnosis	Parkinson's disease, Wilson's disease, Huntington's disease
Prevention	N/A
Treatment	Symptomatic treatment, physical therapy, occupational therapy
Medication	N/A
Prognosis	Variable, generally progressive
Frequency	Rare
Deaths	N/A

Kufor–Rakeb syndrome (KRS) is a rare, inherited neurodegenerative disorder characterized by early-onset parkinsonism, pyramidal degeneration, and cognitive decline. It is also known as Parkinsonism with spasticity, and it is classified as a form of juvenile parkinsonism.

Presentation

Kufor–Rakeb syndrome typically presents in childhood or adolescence. The primary symptoms include parkinsonism, which manifests as bradykinesia, rigidity, and tremor. Additionally, patients often exhibit spasticity, which is an abnormal increase in muscle tone or stiffness. Cognitive decline is also a significant feature, leading to progressive dementia. Other symptoms may include supranuclear gaze palsy, hyperreflexia, and dystonia.

Genetics

Kufor–Rakeb syndrome is caused by mutations in the ATP13A2 gene, which encodes a lysosomal P-type ATPase. This gene is located on chromosome 1p36. The disorder is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to develop the condition.

Pathophysiology

The ATP13A2 protein is involved in the regulation of lysosomal function and ion homeostasis. Mutations in the ATP13A2 gene lead to lysosomal dysfunction, which contributes to the neurodegenerative process observed in Kufor–Rakeb syndrome. The exact mechanisms by which these mutations cause the clinical features of the syndrome are still under investigation.

Diagnosis

Diagnosis of Kufor–Rakeb syndrome is based on clinical evaluation, family history, and genetic testing to identify mutations in the ATP13A2 gene. Neuroimaging studies, such as MRI and CT scans, may show brain atrophy, particularly in the basal ganglia and cerebellum.

Treatment

There is currently no cure for Kufor–Rakeb syndrome. Treatment is primarily symptomatic and supportive. Levodopa and other dopaminergic medications may provide some relief for parkinsonian symptoms, although their effectiveness is often limited. Physical therapy, occupational therapy, and speech therapy can help manage spasticity and improve quality of life.

Prognosis

The prognosis for individuals with Kufor–Rakeb syndrome is generally poor, with progressive neurological decline leading to severe disability. Life expectancy may be reduced, although the rate of progression can vary among individuals.

See also

• Parkinsonism
• Neurodegenerative disorder
• Autosomal recessive
• Lysosome
• Genetic disorder

External links

-

   This article is a medical stub. You can help WikiMD by expanding it!